<DOC>
	<DOCNO>NCT00303498</DOCNO>
	<brief_summary>The aim study determine whether long-term ( ≥ 6 month target dose ) blockade ETA receptor use sitaxsentan show functional benefit subject chronic Heart Failure Left Ventricular Ejection Fraction ≥50 % .</brief_summary>
	<brief_title>A Study Effectiveness Sitaxsentan Sodium Patients With Diastolic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>18 old chronic heart failure evidence diastolic dysfunction echocardiogram , heart imaging , minimum exercise tolerance average time 120 second two treadmill test within 2 week enrollment unstable cardiovascular disease within 4 week screen , history heart attack , cardiac bypass surgery percutaneous intervention , stent placement , within 3 month screen amyloidosis , hypertrophic obstructive restrictive cardiomyopathy , constrictive pericarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>